Selective COX-2 Inhibitors: Road from Success to Controversy and the Quest for Repurposing

The introduction of selective COX-2 inhibitors (so-called ‘coxibs’) has demonstrated tremendous commercial success due to their claimed lower potential of serious gastrointestinal adverse effects than traditional NSAIDs. However, following the repeated questioning on safety concerns, the coxibs ‘con...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Malah, Afaf A., Gineinah, Magdy M., Deb, Pran Kishore, Khayyat, Ahdab N., Bansal, Monika, Venugopala, Katharigatta N., Aljahdali, Anfal S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318302/
https://www.ncbi.nlm.nih.gov/pubmed/35890126
http://dx.doi.org/10.3390/ph15070827

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318302/
https://www.ncbi.nlm.nih.gov/pubmed/35890126
http://dx.doi.org/10.3390/ph15070827

Ejemplares similares